Table 2.
Overall changes in endpoints across treatment steps
| Outcome | Mean ± SD or median [interquartile range]N(missing %) | |||
|---|---|---|---|---|
| Pre-treatment at baseline (visit 1) | Colchicine (visit 2) | Colchicine + XOI (visit 3) | pvalue* | |
| sU (mg/dL) | 9.12 ± 1.48 | 9.69 ± 1.50 | 5.08 ± 0.66 | < 0.0001 |
| 38 (0%) | 31 (18.4%) | 32 (15.8%) | ||
| FMD (% dilation) | 1.93 ± 3.29 | 2.33 ± 2.95 | 3.04 ± 2.36 | 0.40 |
| 38 (0%) | 36 (5.3%) | 31 (18.4%) | ||
| NMD (% dilation) | 17.45 ± 9.55 | 17.98 ± 6.07 | 17.25 ± 6.17 | 0.82 |
| 29 (23.7%) | 25 (34.2%) | 23 (39.5%) | ||
| hsCRP (mg/L) | 4.28 ± 0.46 | 3.9 ± 0.53 | 3.0 ± 0.34 | 0.12 |
| 36 (5.3%)s | 32 (15.8%) | 32 (15.8%) | ||
| ESR (mm/H) | 14.85 ± 8.72 | 12.90 ± 11.84 | 10.81 ± 6.59 | 0.03 |
| 36 (5.3%) | 29 (23.7%) | 31 (18.4%) | ||
| IL-1β (pg/mL) | 2.60 [1.99–3.14] | 2.64 [1.64–3.42] | 2.05 [1.35–2.82] | 0.01** |
| 34 (11%) | 32 (16%) | 28 (26%) | ||
| IL-6 (pg/mL) | 5.23 [3.84–24.74] | 6.00 [2.65–32.66] | 4.69 [2.22–14.90] | 0.02** |
| 34 (11%) | 32 (16%) | 28 (26%) | ||
| MPO (ng/mL) | 160 [63–258] | 150 [83–317] | 182 [69–278] | 0.87** |
| 34 (11%) | 32 (16%) | 28 (26%) | ||
sU serum urate, FMD flow-mediated dilation, NMD nitrate-mediated dilation, hsCRP high-sensitivity C-reactive protein, ESR erythrocyte sedimentation rate, IL-1β interleukin-1β, IL-6 interleukin 6, MPO myeloperoxidase
*p values by univariate mixed-effect model ANOVA except where double asterisk (**) indicates related-samples Friedman’s two-way ANOVA by ranks test